PHRI researchers took part in the American Heart Association Scientific Sessions 2025 in New Orleans.
Shamir Mehta, senior scientist, presented in a late-breaking clinical science session on a meta-analysis comparing complete versus culprit-lesion-only revascularization for acute myocardial infarction. The findings of the study were published simultaneously in The Lancet.
Dr. Shamir Mehta and I discuss the findings of IPD meta-analysis from Complete Revascularization Trialists' Collaboration: Does complete revasc reduce CV death or new MI compared to culprit-only PCI when considering the totality of RCT data? #AHA25 View video here:… pic.twitter.com/kacIgwAmbz
— C. Michael Gibson MD (@CMichaelGibson) November 13, 2025
Mehta also moderated a session on acute MI care, which covered complete revascularization, imaging, antithrombotic therapy, and post-MI treatment.
William McIntyre, scientist, served as the discussant for the session “Primary results from the post-approval study of a next-generation wearable cardioverter defibrillator system: ACE-PAS,” providing commentary and guiding discussion.
In a session on cardiovascular care in cancer patients, Darryl Leong, senior scientist, took part in a debate and presented the CON position—arguing against the statement that permissive cardiotoxicity should be applied in anthracycline cardiomyopathy.
Jeff Healey, senior scientist, served as the discussant for the CLOSURE-AF trial, which examined left atrial appendage closure in patients with atrial fibrillation at high risk of stroke and bleeding.
Hertzel Gerstein, interim executive director and senior scientist, participated in a debate on early incretin therapy for brain health, arguing in favour of starting treatment early.
Harriette Van Spall, senior scientist, participated in several sessions. She moderated Stuck Between a Rock and a Hard Place: Heart Failure and CKD in Critically Ill Patients, presented on Navigating the Crossroads of Hypertension, CKD, and HFpEF, and presented on Addressing Potential for Bias in AI to Ensure Health Equity Advancement. She also presented CKD in HFpEF: A Forgotten Therapeutic Target and served as discussant for the COPILOT HF session.
1st day at #AHA25
Practical strategies for managing HTN and CKD in HFpEF 🫀 pic.twitter.com/czcmBoxEl9
— Sara Ebrahimi, MD, MPH (@SarahEbrahimiii) November 10, 2025
